433 related articles for article (PubMed ID: 30182373)
1. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells.
Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
Mol Carcinog; 2018 Dec; 57(12):1835-1844. PubMed ID: 30182373
[TBL] [Abstract][Full Text] [Related]
2. Epigallocatechin-3-gallate inhibited cancer stem cell-like properties by targeting hsa-mir-485-5p/RXRα in lung cancer.
Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
J Cell Biochem; 2018 Nov; 119(10):8623-8635. PubMed ID: 30058740
[TBL] [Abstract][Full Text] [Related]
3. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
Jiang P; Wu X; Wang X; Huang W; Feng Q
Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
[TBL] [Abstract][Full Text] [Related]
4. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway.
Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q
Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867
[TBL] [Abstract][Full Text] [Related]
5. LncRNA DGCR5 contributes to CSC-like properties via modulating miR-330-5p/CD44 in NSCLC.
Wang R; Dong HX; Zeng J; Pan J; Jin XY
J Cell Physiol; 2018 Sep; 233(9):7447-7456. PubMed ID: 29663359
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
7. NEAT1 acts as an inducer of cancer stem cell-like phenotypes in NSCLC by inhibiting EGCG-upregulated CTR1.
Jiang P; Chen A; Wu X; Zhou M; Ul Haq I; Mariyam Z; Feng Q
J Cell Physiol; 2018 Jun; 233(6):4852-4863. PubMed ID: 29152741
[TBL] [Abstract][Full Text] [Related]
8. Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer.
Li QQ; Xie YK; Wu Y; Li LL; Liu Y; Miao XB; Liu QZ; Yao KT; Xiao GH
Oncotarget; 2017 Feb; 8(7):12067-12080. PubMed ID: 28076844
[TBL] [Abstract][Full Text] [Related]
9. miR-324-5p upregulation potentiates resistance to cisplatin by targeting FBXO11 signalling in non-small cell lung cancer cells.
Ba Z; Zhou Y; Yang Z; Xu J; Zhang X
J Biochem; 2019 Dec; 166(6):517-527. PubMed ID: 31778188
[TBL] [Abstract][Full Text] [Related]
10. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells.
Yao W; Wang L; Huang H; Li X; Wang P; Mi K; Cheng J; Liu H; Gu C; Huang L; Huang J
BMC Cancer; 2020 Apr; 20(1):315. PubMed ID: 32293355
[TBL] [Abstract][Full Text] [Related]
11. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
12. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1.
Cheng R; Lu C; Zhang G; Zhang G; Zhao G
Oncol Rep; 2017 Apr; 37(4):2129-2136. PubMed ID: 28350100
[TBL] [Abstract][Full Text] [Related]
14. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
15. CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC).
Wang Y; Wu Y; Xie S
Bioengineered; 2022 Feb; 13(2):3651-3664. PubMed ID: 35230201
[TBL] [Abstract][Full Text] [Related]
16. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
17. miR-181b/Notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC.
Wang X; Meng Q; Qiao W; Ma R; Ju W; Hu J; Lu H; Cui J; Jin Z; Zhao Y; Wang Y
Stem Cell Res Ther; 2018 Nov; 9(1):327. PubMed ID: 30470250
[TBL] [Abstract][Full Text] [Related]
18. Novel triple‑positive markers identified in human non‑small cell lung cancer cell line with chemotherapy-resistant and putative cancer stem cell characteristics.
Satar NA; Fakiruddin KS; Lim MN; Mok PL; Zakaria N; Fakharuzi NA; Abd Rahman AZ; Zakaria Z; Yahaya BH; Baharuddin P
Oncol Rep; 2018 Aug; 40(2):669-681. PubMed ID: 29845263
[TBL] [Abstract][Full Text] [Related]
19. Green tea polyphenol EGCG reverse cisplatin resistance of A549/DDP cell line through candidate genes demethylation.
Zhang Y; Wang X; Han L; Zhou Y; Sun S
Biomed Pharmacother; 2015 Feb; 69():285-90. PubMed ID: 25661371
[TBL] [Abstract][Full Text] [Related]
20. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
